Health
Sanofi and GSK start Phase II study of their COVID-19 vaccine candidate – European Pharmaceutical Review
The dose finding study will assess the safety, reactogenicity and immunogenicity of the investigational COVID-19 vaccine in 720 participants.
Posted: 24 February 2021 | Hannah Balfour (European Pharmaceutical Review) | No comments yet
The dose finding study will assess the safety, reactogenicity and immunogenicity of the companies investigational COVID-19 vaccine in 720 participants.
Sanofi and GlaxoSmithKline (GSK) have announced the initiation of a new Phase II study of their adjuvanted recombinant protein COVID-19 vaccine candidate.
The Phase II trial is a randomised, double-blind, multi-centre dose finding study and will evaluate…
-
Business20 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?
-
Noosa News20 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
General14 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
Noosa News17 hours agoTips to improve engagement – Proctor